RT Journal Article
SR Electronic
T1 Increasing incidence of parosmia and phantosmia in patients recovering from COVID-19 smell loss
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.28.21262763
DO 10.1101/2021.08.28.21262763
A1 Kathrin Ohla
A1 Maria Geraldine Veldhuizen
A1 Tomer Green
A1 Mackenzie E. Hannum
A1 Alyssa J. Bakke
A1 Shima Moein
A1 Arnaud Tognetti
A1 Elbrich M. Postma
A1 Robert Pellegrino
A1 Liang-Dar Hwang
A1 Javier Albayay
A1 Sachiko Koyama
A1 Alissa Nolden
A1 Thierry Thomas-Danguin
A1 Carla Mucignat-Caretta
A1 Nick S. Menger
A1 Ilja Croijmans
A1 Lina Öztürk
A1 Hüseyin Yanık
A1 Denis Pierron
A1 Veronica Pereda-Loth
A1 Alexia Nunez-Parra
A1 Aldair M. Martinez Pineda
A1 David Gillespie
A1 Michael C. Farruggia
A1 Cinzia Cecchetto
A1 Carl Philpott
A1 Vera Voznessenskaya
A1 Keiland Cooper
A1 Paloma Rohlfs Dominguez
A1 Orietta Calcinoni
A1 Jasper de Groot
A1 Sanne Boesveldt
A1 Surabhi Bhutani
A1 Elisabeth M. Weir
A1 Cara Exten
A1 Paule V. Joseph
A1 Valentina Parma
A1 John E. Hayes
A1 Masha Y. Niv
YR 2021
UL http://medrxiv.org/content/early/2021/08/31/2021.08.28.21262763.abstract
AB Importance Sudden smell loss is a specific early symptom of COVID-19, with an estimated prevalence of ∼40% to 75%. Smell impairment affects physical and mental health, and dietary behavior. Thus, it is critical to understand the rate and time course of smell recovery.Objective To characterize smell function and recovery up to 11 months post COVID-19 infection.Settings, Participants This longitudinal survey of individuals suffering COVID-19-related smell loss assessed disease symptoms and gustatory and olfactory function. Participants (n=12,313) who completed an initial respiratory symptoms, chemosensory function, and COVID-19 diagnosis survey (S1) between April and September 2020 and completed a follow-up survey (S2) between September 2020 and February 2021; 27.5% participants responded (n=3,386), with 1,468 being diagnosed with COVID-19 and suffering co-occurring smell and taste loss at the beginning of their illness.Main Outcomes & Measures Primary outcomes are ratings of smell and taste function on a visual analog scale, and self-report of parosmia (smell distortions) and phantosmia (unexplained smells). Secondary outcomes include a checklist of other COVID-19 symptoms.Results On follow-up (median time since COVID-19 onset ∼200 days), ∼60% of women and ∼48% of men reported less than 80% of their pre-illness smell ability. Taste typically recovered faster than smell, and taste loss rarely persisted if smell recovered. Prevalence of parosmia and phantosmia was ∼10% of participants in S1 and increased substantially in S2: ∼47% for parosmia and ∼25% for phantosmia. Persistent smell impairment was associated with more symptoms overall, suggesting it may be a key marker of long-COVID. During COVID-19 illness, the ability to smell was slightly lower among those who did not recover their pre-illness ability to smell at S2.Conclusions and Relevance While smell loss improves for many individuals who lost it due to COVID-19, the prevalence of parosmia and phantosmia increases substantially over time. Olfactory dysfunction is also associated with wider COVID-19 symptoms and may persist for many months after COVID-19 onset. Taste loss in the absence of smell loss is rare. Persistent qualitative smell symptoms are emerging as common long-term sequelae; more research into treatment options is strongly warranted given that conservative estimates suggest millions of individuals may experience parosmia following COVID-19. Healthcare providers worldwide need to be prepared to treat post COVID-19 secondary effects on physical and mental health.Trial registration This project was pre-registered at OSF: https://osf.io/3e6zc.Question What are the characteristics of smell and taste recovery of COVID-19 patients?Findings In this preregistered observational study of 1,468 participants, smell loss is associated with a higher number of COVID-19 symptoms, and may persist for at least 11 months following disease onset. While a majority of participants report quantitative improvement in their ability to smell, the prevalence of parosmia and phantosmia increases substantially at follow-up. Taste recovers faster than smell, suggesting taste and smell recover separately and can be distinguished by the respondents.Meaning Olfactory dysfunction appears to be a component of long-COVID, with parosmia as a prominent symptom in almost half of those with smell loss. More research into treatment is needed, especially given that olfactory dysfunction is associated with depression and loss of appetite. Health professionals should be aware of these common and long lasting effects.Competing Interest StatementDr. Hayes is a co-founder of Redolynt LLC. Prof. Philpott is a trustee of the charity Fifth Sense. None of the other authors have any conflicts to disclose.Clinical Protocols https://osf.io/3e6zc Funding StatementDeployment of the original GCCR survey and follow-up survey were both supported by an unrestricted gift from James and Helen Zallie to support sensory science research at Penn State. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This longitudinal, observational online cohort study approved by the Office of Research Protections of The Pennsylvania State University (STUDY00014904), entails a follow-up survey (S2) of respondents to the GCCR core survey (S1; https://www.nlm.nih.gov/dr2/COVID-19_BSSR_Research_Tools.pdf) 3,5 between 2 and 10 months after initial participation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon acceptance of publication here: https://osf.io/e68ns/wiki/10_Projects/.